British pharmaceutical company AstraZeneca has become the largest multinational pharmaceutical company in China, deriving 13% of its revenue of $5.8 billion last year from there, amid an acute economic slowdown in the country and d a vast anti-corruption campaign targeting the health sector. care industry.

The question now is whether AstraZeneca has become too aggressive in its ambitions.

Last week, the company revealed that Leon Wang, its executive vice president for international operations and president of its China subsidiary, was under investigation by authorities. The nature of the investigation was unclear, but the announcement followed the recent detention of Eva Yin, a former AstraZeneca executive who is currently chief commercial officer of Beigene, another drug developer in China.

Exclusive STAT+ story

Already have an account? Log in

This article is reserved for STAT+ subscribers

Unlock this article – plus daily coverage and analysis of the pharmaceutical industry – by subscribing to STAT+.

Already have an account? Log in

Individual packages

Group packages

See all packages